Wang Cheng-feng, Zhao Ping, Li Ye-xiong, Shan Yi, Zhao Dong-bing, Tian Yan-tao, Sun Yue-min, Bai Xiao-feng, Che Xu, Qu Hui, Xie Yi-bin, Zheng Rong, Zhou Chun-wu
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing 100021, China.
Zhonghua Yi Xue Za Zhi. 2010 Jan 12;90(2):92-5.
To study the role of (125)I seed implantation in the treatment of unresectable pancreatic cancer.
From April 2004 to march 2006, 66 untreated patients with locally advanced pancreatic cancer (LAPC) were randomized into two groups: Group A: (125)I seeds implantation (n = 31) and Group B: control (n = 34). The objective tumor response, clinical benefit response, toxicity, complications and survival of two groups were observed.
In Group A, the overall response rate (PR + NC) was 80.6%. Clinical benefit response rate was 54.8%. No toxicity was observed. Gastrointestinal hemorrhage and pancreatic fistula occurred in 1 patient respectively in Group A. The survival rates of 6 and 12 months were 56.0% vs 31.4% and 16.8% vs 2.9% respectively in two groups (P < 0.05). The median survival time of two groups was 8.0 months vs 4.0 months (P < 0.05).
(125)I seed implantation is a simple, safe and effective method in the treatment of locally advanced pancreatic cancer.
